BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107 Asset Class: Stock



Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	7,378,885,000		5,754,472,000		7,082,482,000	
Common stock capital		13,743,767,000		14,079,285,000		13,031,918,000
Fixed assets	28,684,824,000		29,048,773,000		29,804,024,000	
Equity capital of a company		-108,125,000		352,287,000		-42,947,000
Cash and cash equivalents	1,268,493,000		800,775,000		2,676,614,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		5,672,617,000		5,339,857,000		6,565,853,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		30,499,218,000		29,111,100,000		30,363,599,000
Different income		-		-		-
Other liabilities		1,161,686,000		1,036,536,000		809,679,000
Total assets	36,063,710,000	36,063,710,000	34,803,245,000	34,803,245,000	36,886,506,000	36,886,506,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	20,270	19,900	19,100
Equity ratio	3.14%	4.72%	0.13%
Debt-equity ratio	3,087.65%	2,019.31%	76,747.37%

Others			
	2023	2022	2021
Tax Expense Rate	-56.67%	-64.34%	8.50%

BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	11,819,208,000	10,576,257,000	10,573,980,000
Net income	-799,014,000	-292,917,000	-1,188,538,000
EBIT	899,663,945	1,224,425,362	386,821,023
Operating income before taxes	-526,377,000	-167,939,000	-1,283,822,000
Cash Flow	1,344,288,000	-1,040,180,000	1,727,643,000
Net interest income	-1,853,120,000	-1,973,609,000	-1,854,270,000
Research and development expenses	815,210,000	688,680,000	582,985,000
Income taxes	298,280,000	108,053,000	-109,074,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	395,392	360,390	375,404

Board of Directors

John Paulson	Chairman of Supervisory Board
Amy Wechsler	Member of Supervisory Board
Richard Mulligan	Member of Supervisory Board
Brett Icahn	Member of Supervisory Board
Robert Power	Member of Supervisory Board
Russel Robertson	Member of Supervisory Board
Sarah Kavanagh	Member of Supervisory Board
Steven Miller	Member of Supervisory Board
Thomas Ross	Member of Supervisory Board

Members of Management Board

Thomas Appio	Chairman of Managing Board	
Tage Ramakrishna	Member of Executive Committee	
Cees Heiman	Member of Executive Committee	
Fernando Zarate	Member of Executive Committee	
Graham Jackson	Member of Executive Committee	
Jeff Hartness	Member of Executive Committee	
Kathleen Fitzpatrick	Member of Executive Committee	
Mirza Dautbegovic	Member of Executive Committee	
Seana Carson	Member of Executive Committee	
Tom Vadaketh	Member of Executive Committee	